Capricor Therapeutics, Inc. (CAPR)
Pre-Market:
| Previous Close | 5.41 |
| Open | 5.48 |
| Bid | 5.32 x 100 |
| Ask | 5.38 x 100 |
| Day's Range | 5.27 - 5.68 |
| 52 Week Range | 2.68 - 8.22 |
| Volume | |
| Avg. Volume | 324,900 |
| Market Cap | 167.911M |
| Beta (5Y Monthly) | 4.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.83 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.00 |
Simply Wall St.Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
GlobeNewswireCapricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
-Company Aligned with FDA on Demonstration of Non-Clinical Comparability; Allowing for Immediate Use of San Diego Manufacturing Facility- -FDA Feedback Supports Requests for a Pre-BLA Meeting and Subsequent Rolling BLA Submission Following Upcoming Q2 Type-B FDA Meeting- -Company Granted Subsequent Type-B Clinical Meeting with FDA in Second Quarter to Continue to Discuss Pathway to BLA- -Capricor Management to Host Virtual Investor Webcast to Discuss Latest Program Updates on Monday, April 29 at
ZacksWall Street Analysts Predict a 218.18% Upside in Capricor (CAPR): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 218.2% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
